Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 12/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293347 | 0.88 | AR (0.44) | CNR2ARPGRS1PR1 | |
| SCHEMBL3290401 | 0.87 | AR (0.47) | CNR2ARPGRRXRARXRB | |
| SCHEMBL3410635 | 0.86 | UBE2M (0.44) | CNR2ARPGRRXRARXRB | |
| SCHEMBL3412274 | 0.85 | CNR2 (0.41) | CNR2ARPGRRXRARXRB | |
| SCHEMBL3288362 | 0.85 | AR (0.42) | CNR2ARPGRS1PR1 | |
| SCHEMBL3410457 | 0.84 | CNR2 (0.41) | CNR2ARPGRRXRARXRB | |
| SCHEMBL1377030 | 0.84 | PGR (0.47) | PGR | |
| SCHEMBL3417092 | 0.84 | AR (0.40) | CNR2ARPGRRXRARXRB | |
| SCHEMBL3289079 | 0.83 | AR (0.48) | CNR2ARPGRPOLQS1PR1 | |
| SCHEMBL3414127 | 0.82 | CNR2 (0.44) | CNR2ARPGRRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | claimed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | claimed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | claimed |
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-7723385-B2 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2051980-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2008021924-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR3C2, NR5A1 | CNR2 677/4885AR 1/4885PGR 24/4885 |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | AR, NR3C2, NR5A1 | CNR2 677/4885AR 1/4885PGR 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.